Surgery Partners (SGRY) Stock Forecast & Price Target

Surgery Partners is viewed favorably because it is the nation’s fifth largest ASC system with 120 consolidated facilities and a cleaner, more focused pure-play outpatient profile after the Idaho Falls divestiture, which reduces investor overhang and improves balance sheet and cash conversion. Its growth case is supported by management’s push into high-acuity musculoskeletal and cardiology procedures, continued OR capacity investment, and physician recruiting, alongside Medicare rule changes that could expand the addressable market. The company’s strategic value is further underscored by takeover interest at $25.00/share and a competing $28.00 bid, with implied valuations around 13.3x FY2027 Adjusted EBITDA-NCI of $443MM, reinforcing confidence in durable double-digit EBITDA growth.

Surgery Partners is vulnerable to a weaker operating trajectory because the downside case assumes FY27E EBITDA, adjusted for the Idaho Falls divestiture, falls 10% below base estimates due to slower ramp-up of new assets, recruiting headwinds, and limited traction in expanding cardio capabilities. The valuation also embeds only about a 10.5x to 10.7x enterprise multiple, signaling limited confidence in sustained growth and leaving little room for execution missteps. Its outlook is further pressured by reliance on managed care and Medicare reimbursement, integration risk, physician retention challenges, labor cost inflation, revenue concentration, and leverage.